Trial Profile

A Randomized, Double-Blind, Active-Controlled, Parallel Group, Stratified, Multi-Center, 12-Week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm 100/10 microg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Fluticasone (100 microg Twice Daily) and Formoterol (10 microg Twice Daily) Alone in Adolescent and Adult Patients With Mild to Moderate Asthma.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Formoterol/fluticasone propionate (Primary) ; Fluticasone propionate; Formoterol
Indications Asthma
Focus Registrational; Therapeutic Use
Sponsors SkyePharma AG

28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
30 Apr 2008 Status changed from in progress to completed, following the announcement that the primary endpoints had been met.
02 Nov 2007 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com